CoreCivic delivered higher-than-expected revenue and earnings in the latest quarter, yet the market responded negatively, likely reflecting concerns raised on the earnings call about contract modifications, leadership changes, and the impact of recent asset sales. CEO Lucibeth Mayberry cited increased occupancy rates and heightened enforcement activity by government partners as key drivers, noting, “Federal partners, primarily ICE and the U.S. Marshals Service, comprised 53% of CoreCivic’s total revenue in the third quarter.” The company also emphasized the significance of its Clinical Solutions Pharmacy acquisition and strong demand from ICE as important contributors. However, management acknowledged that some of the positive momentum could be offset in coming quarters by modifications to existing management contracts at facilities recently sold to the federal government.
Is now the time to buy CXW? Find out in our full research report (it’s free for active Edge members).
CoreCivic (CXW) Q3 2026 highlights:
- Revenue $744.1 million vs S&P analysts’ estimates of $705.8 million (28.2% year-on-year growth, 5.4% beat)
- Adjusted EPS $0.49 vs S&P analysts’ estimates of $0.43 (14% beat)
- Adjusted EBITDA $117.8 million vs analyst estimates of $109.3 million (15.8% margin, 7.8% beat)
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $1.77 at the midpoint, a 6.6% increase
- EBITDA guidance $444 million at the midpoint for the full year, above analyst estimates of $440.1 million
- Operating margin 9%, in line with the same quarter last year
- Market capitalization $2.44 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from CoreCivic’s Q3 earnings call
- Greg Gibas (Northland Securities) asked about ICE enforcement levels and post-election demand. CEO Lucibeth Mayberry responded that ICE’s needs are stable, with secure funding allowing continued use of contracted beds, and she does not expect material changes regardless of election outcomes.
- Greg Gibas (Northland Securities) followed up on 2027 expectations and facility ramping. CFO David Garfinkle provided a rough estimate of ongoing EBITDA contributions, clarifying that some new facilities would not be fully utilized until late next year and that guidance would be finalized in February.
- Joe Gomes (Noble Capital) questioned the sustainability of operating facilities over 100% capacity and associated costs. Garfinkle explained that high occupancy is typically manageable due to transient populations, and additional costs are minimal, while Mayberry noted facility design supports operational flexibility without overcrowding.
- Joe Gomes (Noble Capital) asked about per diem rate increases and partner pushback. Garfinkle answered that federal per diem increases are contractually built-in, while recent state-level negotiations have been positive due to shared inflationary pressures.
- Marla Marin (Zacks) inquired about the impact of elections and ICE’s use of alternative facilities. Mayberry said she would urge ICE to move quickly on asset acquisitions, noting no current signals that the election would alter demand, and observed that ICE appears to be retreating from less traditional detention solutions.
Catalysts in upcoming quarters
Looking forward, StockStory analysts will watch (1) the pace and financial impact of management contract modifications at facilities sold to the federal government, (2) the continued ramp-up and profitability of newly activated contracts and facilities, and (3) any developments around further asset sales to ICE. The execution of share repurchase plans and success of the Clinical Solutions Pharmacy integration will also be key markers for tracking CoreCivic’s strategy.
CoreCivic currently trades at $28.23, down from $30.52 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
Our favorite stocks right now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
